Gefitinib Trial in a Fanconi's Anemia Patient with Multiple Squamous Cell Carcinomas and Hepatocellular Carcinoma.
- Author:
Hae Sun JUNG
1
;
Gun Woo BYUN
;
Kyoung Eun LEE
;
Yeung Chul MUN
;
Seung Hyun NAM
;
Jung Mi KWON
;
Shi Nae LEE
;
Seock Ah IM
;
Chu Myong SEONG
;
Soon Nam LEE
Author Information
1. Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea. snlee@ewha.ac.kr
- Publication Type:Case Report
- Keywords:
Fanconi's anemia;
Squamous cell carcinoma;
Gefitinib
- MeSH:
Bone Marrow;
Carcinoma, Hepatocellular*;
Carcinoma, Squamous Cell*;
Congenital Abnormalities;
DNA;
Fanconi Anemia*;
Humans;
Pancytopenia
- From:Cancer Research and Treatment
2005;37(6):370-373
- CountryRepublic of Korea
- Language:English
-
Abstract:
FA (Fanconi's Anemia) is an autosomal recessive disorder that is characterized by pancytopenia with bone marrow hypoplasia, diverse congenital abnormalities and an increased predisposition towards malignancy. The mainstay of the treatment for these cancers has been surgery, because of the hypersensitive reactions of FA patients to DNA cross- linking agents or radiation. Therefore, there has been no effective therapy for advanced squa mous cell carcinoma. We report here on a patient suffering from advanced multiple squamous cell carcinoma and hepatocellular carcinoma along with an FA, and this patient was treated with gefitinib.
